Nrx pharmaceuticals (nasdaq:nrxp) to launch hope therapeutics, inc. at the bio ceo & investor conference 2024

Hope shares currently owned by nrxp with planned share dividend to existing nrxp shareholders hope has now completed initial manufacture of ketamine for iv infusion and plans to file fda new drug application for treatment of acute suicidality upon demonstration of 2-year shelf stability (expected q2 2024) hope plans to file patient-level data from two well-controlled clinical trials comparing ketamine to placebo in patients with acute suicidality and depression, which demonstrated a statistically significant benefit (p
NRXP Ratings Summary
NRXP Quant Ranking